Information regarding impact on healthcare systems of relapsed or refractory (R/R) FLT3 mutated (FLT3mut) acute myeloid leukemia (AML) is scarce.
To assess the time and reimbursement associated with hospitalizations of patients with R/R FLT3mut AML in a tertiary Spanish hospital.
Retrospective review of medical charts identified patients aged ≥18 years with R/R FLT3mut AML between 1998 and 2018. Data were collected from the date of first diagnosis of R/R FLT3mut AML (index) until death or loss to follow-up. The primary endpoint was duration and frequency of hospitalization, use of outpatient resources and transfusion burden. Reimbursement associated with hospitalizations (including associated chemotherapy) was also assessed.
Thirty-eight patients were eligible for inclusion. Their median age was 52 years and 30 (79%) received intensive salvage chemotherapy, FLAG-IDA based regimens were the most frequent (24 patients, 63%). Overall, there were 150 hospitalizations (mean 3.9/patient; mean duration 21 days). Patients spent a mean of 24% of the study period in hospital. Total mean reimbursement was €108,293 per patient; the majority (€89,834) attributable to inpatient stays (€22,576 /hospitalization). During chemotherapy period (prior to first alloHSCT), there were 73 hospitalizations (mean duration 22 days); mean reimbursement was €19,776 per hospitalization and €49,819 per patient. AlloHSCT (n = 16) involved 77 hospitalizations (mean duration 21 days); mean reimbursement €25,231/hospitalization and €131,515 per patient.
Data from this study suggest that there is a substantial healthcare resource utilization and cost burden on R/R FLT3mut AML patients in Spain receiving active treatments.

Author